Adicet Bio
ACET
99 hedge funds and large institutions have $370M invested in Adicet Bio in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 29 reducing their positions, and 24 closing their positions.
12% more call options, than puts
Call options by funds: $843K | Put options by funds: $752K
3% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 29
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
0.46% less ownership
Funds ownership: 6.49% → 6.03% (-0.46%)
3% less funds holding
Funds holding: 102 → 99 (-3)
37% less capital invested
Capital invested by funds: $591M → $370M (-$221M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$55.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.5M |
| 3 |
CAC
Cowen and Company
New York
|
+$10.9M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.36M |
| 5 |
BlackRock
New York
|
+$6.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$29.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.5M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.7M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6M |
ACET Hedge Fund Activity: Q4 2022 in Review
99 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q4 2022, worth a combined $370M — down 37% from $591M a quarter earlier.
Fund positioning in ACET was balanced in Q4 2022: 24 funds opened new positions, 24 closed out, 30 added to existing stakes and 29 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $55.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $29.3M sold.
- 99 institutional investors held Adicet Bio (ACET) as of Q4 2022, down from 102 in Q3 2022.
- Funds reported $370M of Adicet Bio stock for Q4 2022, down 37% quarter-over-quarter.
- 24 funds opened new Adicet Bio positions in Q4 2022 and 24 closed out, a net change of 0 holders.
- The largest Adicet Bio buyer in Q4 2022 was EcoR1 Capital, an estimated $55.5M added.
- The largest Adicet Bio seller in Q4 2022 was RA Capital Management, an estimated $29.3M sold.
Based on aggregated 13F filings for Q4 2022.